

Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analysis series

ME Rahman Shuvo*MBBS, Max Schwiening*BA, Felipe Soares PhD, Oliver Feng PhD,
Susana Abreu PhD, Niki Veale MBBS, William Thomas MBBS, AA Roger Thompson PhD,
Richard J Samworth PhD, Nicholas W Morrell PhD, Stefan J Marciniak PhD,
Elaine Soon PhD (0000-0002-5744-5014)

SUPPLEMENT

Statistical Methods

Raw data and pre-processing: In each study, we do not have access to individual patient data, but the following measurements are reported:

Study leader and country;
Cohort size;
AUC and associated 95% confidence interval;
Age: mean and spread;
Biomarker level: mean and spread;
type of outcome measured (mortality or critical illness)

Converting spread measurements or confidence intervals into a standard error for the mean estimate: The spread is given as either a SD estimate $\hat{\sigma}$, a 95% confidence interval $[\hat{l}, \hat{u}]$, an IQR $[\hat{q}, \hat{Q}]$ or a range $[\hat{m}, \hat{M}]$. Under the assumption that the age and biomarker levels are normally distributed, we converted the IQR and range measurements into SD estimates via

$$\hat{\sigma}^{CI} = \frac{\sqrt{\hat{n}(\hat{u} - \hat{l})}}{2\Phi^{-1}(0.95)}, \quad \hat{\sigma}^{IQR} = \frac{\hat{Q} - \hat{q}}{2\Phi^{-1}(3/4)} \quad \text{and} \quad \hat{\sigma}^{range} = \frac{\hat{M} - \hat{m}}{2\sqrt{2\log 2}}, \quad (1)$$

where \hat{n} is the cohort size. The standard error of the mean estimate was then calculated as $\hat{\sigma}/\sqrt{\hat{n}}$.

Pooling data from subgroups: Sometimes, the age and biomarker information are reported separately for different subgroups of patients (e.g. in different hospitals or wards) of sizes n_1, \dots, n_K (with $\sum_{k=1}^K n_k = n$), in which case we aggregated the individual mean and variance estimates $\hat{\mu}_1, \dots, \hat{\mu}_K$ and $\hat{\sigma}_1^2, \dots, \hat{\sigma}_K^2$ via

$$\hat{\mu} = \frac{1}{n} \sum_{k=1}^K n_k \hat{\mu}_k \quad \text{and} \quad \hat{\sigma}^2 = \frac{1}{n} \sum_{k=1}^K n_k \hat{\sigma}_k^2 + (\hat{\mu}_k - \hat{\mu})^2.$$

The reasoning behind this is that if Z_{k1}, \dots, Z_{kn_k} are random variables with mean μ_k and variance σ_k^2 for $1 \leq k \leq K$, then letting Z be drawn uniformly at random from $\{Z_k : 1 \leq k \leq K\}$

$K, 1 \leq k \leq n_k\}$, we have

$$\mu = E(Z) = \frac{1}{n} \sum_{k=1}^K n_k \mu_k \quad \text{and} \quad \sigma^2 = E(Z - \mu)^2 = \frac{1}{n} \sum_{k=1}^K n_k \sigma_k^2 + (\mu_k - \mu)^2 .$$

Statistical meta-analysis (Covi dMeta. xls): Ideally, we would build a logistic regression model that includes age, gender, levels of different biomarkers, country, type of patient (ICU or non-ICU) etc. as covariates. However, because individual patient data is not available, the current approach is to study the biomarkers individually and determine whether or not there is any significant difference in

- Ability of a single biomarker to predict mortality, as measured by AUC;
- Biomarker level at admission;
- Age

between European/North American and Asian cohorts.

Biomarker level and age: Since the mean estimates for individual studies were found to exhibit high levels of heterogeneity within both the European/North American and Asian parts of the overall dataset, we fitted the random effects model

$$\bar{Y}_{ij} = a_i + b_j + \varepsilon_{ij} \quad \text{for } i = 1, 2, j = 1, \dots, N_i \quad (2)$$

using the R package `net a`. Here, N_1 and N_2 are the total number of studies from Europe ($i = 1$) and Asia ($i = 2$) respectively, a_1, a_2 are the (fixed) baseline means for Europe and Asia, \bar{Y}_{ij} is the mean for the j^{th} study in region i (with n_{ij} participants), $\{b_j \sim N(0, \tau_i^2) : 1 \leq i \leq 2, 1 \leq j \leq N_i\}$ are independent random effects, and $\varepsilon_{ij} \sim N(0, \sigma_{ij}^2/n_{ij})$ are independent noise variables.

The output from each meta-analysis (recorded in the RData files and summary sheets in Covi dMeta. xls) consists of estimates \hat{a}_1, \hat{a}_2 of the European/North American and Asian baseline means, together with 95% confidence intervals for both, as well as a p-value for testing

$$H_0 : a_1 = a_2 \quad \text{against} \quad H_1 : a_1 \neq a_2.$$

Further statistical details: Consider first the simpler model where the σ_{ij} are known and $\tau_i = 0$ for $i = 1, 2$ (i.e. there are no random effects). Then the MLEs of a_1 and a_2 are given by

$$\tilde{a}_i = \underset{\mu}{\operatorname{argmin}} \sum_{j=1}^{N_i} \frac{n_{ij}}{2\sigma_{ij}^2} (\bar{Y}_{ij} - \mu)^2 = \frac{\sum_{j=1}^{N_i} w_{ij} \bar{Y}_{ij}}{\sum_{j=1}^{N_i} w_{ij}}$$

for $i = 1, 2$, where $w_{ij} = n_{ij}/\sigma_{ij}^2$ are the inverse variance weights. In the model (2), the estimates take the form

$$\hat{a}_i = \frac{\sum_{j=1}^{N_i} \hat{w}_{ij} \bar{Y}_{ij}}{\sum_{j=1}^{N_i} \hat{w}_{ij}} \quad \text{with} \quad \hat{w}_{ij} = \frac{\hat{\sigma}_{ij}^2}{n_{ij}} + \hat{\tau}_i^2 \quad^{-1},$$

where the estimates $\hat{\tau}_1^2, \hat{\tau}_2^2$ of the variances of the random effects are obtained by e.g. MLE or restricted maximum likelihood (REML), and the variance estimates $\hat{\sigma}_{ij}^2$ from the individual studies are plugged in.

AUC scores for single biomarkers: The AUC scores for a given biomarker take values in $[0, 1]$ and are not normally distributed, so following the approach of Debray et al. (2017, 2019), we first logit-transformed the reported AUC scores p_{ij} and confidence intervals $[p_{ij}^l, p_{ij}^u]$ for individual studies, and then obtained a standard error for $\text{logit}(p_{ij}) = \log p_{ij}/(1 - p_{ij})$ via (1). We then fitted a random effects model (2) with $\text{logit}(p_{ij})$ in place of Y_{ij} , and then applied the inverse logit transform $t \rightarrow 1/(1 + e^{-t})$ to the resulting estimates to obtain pooled AUCs (and associated 95% confidence intervals) for the European, Asian and overall datasets respectively. For the biomarker under consideration, this analysis also yields a p-value for the significance of the difference between the AUC scores in European and Asian countries.

At the population level, the AUC for a classifier that assigns a score to each patient is given by $P(S_1 \geq S_0)$, where S_1 is the score for a randomly drawn patient from class 1 (i.e. who goes on to die) and S_0 is the score for a randomly drawn patient from class 0 (i.e. who survives).

Sensitivity analyses

Sensitivity analyses were performed by serially excluding each study to determine the implications of individual studies on the pooled AUC. No individual study had a significant implication for the pooled AUCs for either European/N.American or the Asian cohorts (Supplementary Tables 1-5).

Pooled AUC Europe/NA	Lower Limit Europe/NA	Upper Limit Europe/NA	Pooled AUC Asia	Lower Limit Asia	Upper Limit Asia	p-value	Study omitted
0.6728	0.6294	0.7133	0.8267	0.7958	0.8538	4.629E-10	None
0.6759	0.6306	0.7181	0.8267	0.7958	0.8538	1.9685E-09	Soon (Cambridge)
0.6722	0.6262	0.7152	0.8267	0.7958	0.8538	1.1395E-09	Soares (Spain)
0.6757	0.6304	0.7180	0.8267	0.7958	0.8538	1.9182E-09	van Dam (Netherlands)
0.6566	0.6220	0.6896	0.8267	0.7958	0.8538	8.6597E-14	Aloisio (Italy)
0.6724	0.6266	0.7151	0.8267	0.7958	0.8538	1.0607E-09	Peiro (Spain)
0.6785	0.6348	0.7193	0.8267	0.7958	0.8538	1.976E-09	Manocha (USA)
0.6714	0.6257	0.7142	0.8267	0.7958	0.8538	8.5351E-10	Montrucchio (Italy)
0.6718	0.6264	0.7141	0.8267	0.7958	0.8538	7.7371E-10	Pieri (Italy)
0.6670	0.6223	0.7089	0.8267	0.7958	0.8538	1.957E-10	Muinos (Spain)
0.6779	0.6347	0.7184	0.8267	0.7958	0.8538	1.4483E-09	Kara (USA)
0.6669	0.6235	0.7076	0.8267	0.7958	0.8538	1.078E-10	Laguna-Goya (Spain)
0.6722	0.6266	0.7148	0.8267	0.7958	0.8538	9.6236E-10	Myrhe (Norway)
0.6784	0.6347	0.7192	0.8267	0.7958	0.8538	1.928E-09	Donoso-Navarro (Spain)
0.6753	0.6299	0.7176	0.8267	0.7958	0.8538	1.7903E-09	Macias-Munoz (Spain)
0.6739	0.6279	0.7168	0.8267	0.7958	0.8538	1.6296E-09	Rubio-Rivas (Spain)
0.6746	0.6294	0.7167	0.8267	0.7958	0.8538	1.3959E-09	Mueller (USA)
0.6780	0.6337	0.7193	0.8267	0.7958	0.8538	2.1939E-09	Pouw (Netherlands)
0.6766	0.6314	0.7187	0.8267	0.7958	0.8538	2.2088E-09	Smilowitz (USA)
0.6722	0.6265	0.7148	0.8267	0.7958	0.8538	9.7217E-10	Omland (Norway)
0.6686	0.6241	0.7103	0.8267	0.7958	0.8538	2.6866E-10	Dolci (Italy)
0.6705	0.6251	0.7130	0.8267	0.7958	0.8538	6.0326E-10	Oliva (Italy)
0.6728	0.6294	0.7133	0.8297	0.8001	0.8557	8.7022E-11	Asghar (Pakistan)
0.6728	0.6294	0.7133	0.8247	0.7930	0.8524	1.1669E-09	Cheng (China)
0.6728	0.6294	0.7133	0.8293	0.7980	0.8567	3.2389E-10	Tahtasakal (Turkey)
0.6728	0.6294	0.7133	0.8294	0.7989	0.8562	1.8498E-10	Chen L (China)
0.6728	0.6294	0.7133	0.8288	0.7977	0.8561	3.2087E-10	Zhang J (China)
0.6728	0.6294	0.7133	0.8264	0.7939	0.8547	1.3448E-09	Huang (China)
0.6728	0.6294	0.7133	0.8249	0.7928	0.8530	1.4766E-09	Cheng A (China)
0.6728	0.6294	0.7133	0.8237	0.7919	0.8516	1.6089E-09	Luo Y (China)
0.6728	0.6294	0.7133	0.8282	0.7959	0.8563	7.6537E-10	Keski (Turkey)
0.6728	0.6294	0.7133	0.8265	0.7940	0.8548	1.3139E-09	Zhang L (China)
0.6728	0.6294	0.7133	0.8261	0.7944	0.8539	8.8744E-10	Bastug (Turkey)
0.6728	0.6294	0.7133	0.8283	0.7965	0.8561	5.5814E-10	Pan (China)
0.6728	0.6294	0.7133	0.8231	0.7919	0.8506	1.3213E-09	Luo (China)
0.6728	0.6294	0.7133	0.8262	0.7939	0.8543	1.2356E-09	Liang (China)
0.6728	0.6294	0.7133	0.8264	0.7943	0.8545	1.0568E-09	Han (China)
0.6728	0.6294	0.7133	0.8275	0.7951	0.8558	1.0157E-09	Duan (China)
0.6728	0.6294	0.7133	0.8286	0.7968	0.8564	5.2922E-10	Wang D (China)
0.6728	0.6294	0.7133	0.8276	0.7957	0.8554	6.8295E-10	Gao Y (China)
0.6728	0.6294	0.7133	0.8234	0.7986	0.8457	1.4571E-11	Okuyan (Turkey)
0.6728	0.6294	0.7133	0.8288	0.7976	0.8561	3.3895E-10	Genc (Turkey)
0.6728	0.6294	0.7133	0.8268	0.7943	0.8550	1.1898E-09	Li Y (China)
0.6728	0.6294	0.7133	0.8228	0.7931	0.8490	5.3769E-10	Wu W (China)
0.6728	0.6294	0.7133	0.8279	0.7955	0.8561	8.9683E-10	Qin JJ (China)
0.6728	0.6294	0.7133	0.8271	0.7949	0.8552	9.6175E-10	Zeng HL (China)
0.6728	0.6294	0.7133	0.8286	0.7968	0.8563	5.158E-10	Bintoro (Indonesia)
0.6728	0.6294	0.7133	0.8268	0.7948	0.8547	9.1147E-10	Xu JB (China)
0.6728	0.6294	0.7133	0.8275	0.7950	0.8558	1.0443E-09	Zhao Y (China)
0.6728	0.6294	0.7133	0.8282	0.7965	0.8558	5.3729E-10	Saji (Japan)

0.6728	0.6294	0.7133	0.8223	0.7933	0.8481	4.0471E-10	Bilgir (Turkey)
0.6728	0.6294	0.7133	0.8290	0.7976	0.8565	3.6033E-10	Guneyesu (Turkey)
0.6728	0.6294	0.7133	0.8253	0.7934	0.8531	1.1591E-09	Li J (China)
0.6728	0.6294	0.7133	0.8268	0.7945	0.8549	1.0518E-09	Wang F (China)

Supplementary Table 1

Pooled AUCs for CRP calculated with omitting a single study at a time. The first line (in bold) shows the summary from all studies with no omissions.

Pooled AUC Europe/NA	Lower Limit Europe/NA	Upper Limit Europe/NA	Pooled AUC Asia	Lower Limit Asia	Upper Limit Asia	p-value	Study omitted
0.6884	0.6566	0.7185	0.7895	0.7564	0.8192	5.3114E-06	None
0.6886	0.6557	0.7197	0.7895	0.7564	0.8192	6.9417E-06	Soon (Cambridge)
0.6882	0.6543	0.7202	0.7895	0.7564	0.8192	8.2452E-06	Soares (Spain)
0.6866	0.6536	0.7179	0.7895	0.7564	0.8192	4.8748E-06	Gomez (Spain)
0.6874	0.6543	0.7187	0.7895	0.7564	0.8192	5.75E-06	Maeda (USA)
0.6718	0.6473	0.6954	0.7895	0.7564	0.8192	1.5102E-08	Aloisio (Italy)
0.6849	0.6522	0.7159	0.7895	0.7564	0.8192	3.2088E-06	Peiro (Spain)
0.6892	0.6565	0.7202	0.7895	0.7564	0.8192	7.658E-06	Myrhe (Norway)
0.6914	0.6582	0.7228	0.7895	0.7564	0.8192	1.3108E-05	Manocha (USA)
0.6869	0.6540	0.7180	0.7895	0.7564	0.8192	4.9141E-06	Pieri (Italy)
0.6868	0.6531	0.7188	0.7895	0.7564	0.8192	6.0822E-06	Muinos (Spain)
0.6873	0.6545	0.7184	0.7895	0.7564	0.8192	5.3418E-06	Gavin (USA)
0.6864	0.6536	0.7175	0.7895	0.7564	0.8192	4.4513E-06	Laguna-Goya (Spain)
0.6915	0.6582	0.7230	0.7895	0.7564	0.8192	1.3767E-05	Chocron (France)
0.6921	0.6594	0.7230	0.7895	0.7564	0.8192	1.3386E-05	Macias-Munoz (Spain)
0.6949	0.6655	0.7228	0.7895	0.7564	0.8192	1.1215E-05	Donoso-Navarro (Spain)
0.6892	0.6561	0.7205	0.7895	0.7564	0.8192	8.3615E-06	Goudot (France)
0.6916	0.6580	0.7232	0.7895	0.7564	0.8192	1.4498E-05	Rubio-Rivas (Spain)
0.6866	0.6536	0.7178	0.7895	0.7564	0.8192	4.762E-06	Mueller (USA)
0.6905	0.6572	0.7218	0.7895	0.7564	0.8192	1.086E-05	Pouw (Netherlands)
0.6925	0.6593	0.7237	0.7895	0.7564	0.8192	1.5618E-05	Smilowitz (USA)
0.6913	0.6585	0.7223	0.7895	0.7564	0.8192	1.1715E-05	Omland (Norway) Petersen-Urbe (Germany)
0.6861	0.6529	0.7174	0.7895	0.7564	0.8192	4.4878E-06	
0.6884	0.6566	0.7185	0.7880	0.7539	0.8184	1.0166E-05	Yao (China)
0.6884	0.6566	0.7185	0.7913	0.7574	0.8216	4.9517E-06	Asghar (Pakistan)
0.6884	0.6566	0.7185	0.7918	0.7582	0.8219	4.0421E-06	Sharif (Pakistan)
0.6884	0.6566	0.7185	0.7923	0.7589	0.8222	3.4047E-06	Tahtasakal (Turkey)
0.6884	0.6566	0.7185	0.7903	0.7562	0.8208	6.5837E-06	Ke (China)
0.6884	0.6566	0.7185	0.7908	0.7567	0.8212	5.9499E-06	Kucukceran (Turkey)
0.6884	0.6566	0.7185	0.7895	0.7554	0.8200	7.8759E-06	Selcuk (Turkey)
0.6884	0.6566	0.7185	0.7923	0.7590	0.8221	3.2284E-06	Soni (India)
0.6884	0.6566	0.7185	0.7890	0.7549	0.8196	8.6246E-06	Luo HC (China)
0.6884	0.6566	0.7185	0.7890	0.7548	0.8196	8.7767E-06	Chen L (China)
0.6884	0.6566	0.7185	0.7897	0.7555	0.8203	7.659E-06	Wang Z (China)
0.6884	0.6566	0.7185	0.7921	0.7586	0.8221	3.6913E-06	Chen H (China)
0.6884	0.6566	0.7185	0.7872	0.7534	0.8175	1.086E-05	Qin ZJ (China)
0.6884	0.6566	0.7185	0.7920	0.7587	0.8218	3.4374E-06	Zhang J (China)
0.6884	0.6566	0.7185	0.7901	0.7558	0.8206	7.2557E-06	Huang Y (China)
0.6884	0.6566	0.7185	0.7861	0.7524	0.8164	1.2974E-05	Cheng A (China)
0.6884	0.6566	0.7185	0.7895	0.7553	0.8200	8.0692E-06	Ye W (China)
0.6884	0.6566	0.7185	0.7844	0.7526	0.8130	8.731E-06	Liu Q (China)
0.6884	0.6566	0.7185	0.7865	0.7525	0.8169	1.3153E-05	Luo Y (China)
0.6884	0.6566	0.7185	0.7878	0.7536	0.8184	1.1083E-05	Keski (Turkey)
0.6884	0.6566	0.7185	0.7857	0.7520	0.8159	1.3756E-05	Zhang L (China)

0.6884	0.6566	0.7185	0.7921	0.7587	0.8220	3.5069E-06	Liang (China)
0.6884	0.6566	0.7185	0.7873	0.7537	0.8173	9.66E-06	Bastug (Turkey)
0.6884	0.6566	0.7185	0.7895	0.7554	0.8199	7.5685E-06	Wang P (China)
0.6884	0.6566	0.7185	0.7936	0.7615	0.8224	1.456E-06	Cheng S (China)
0.6884	0.6566	0.7185	0.7902	0.7561	0.8207	6.8324E-06	Wang D (China)
0.6884	0.6566	0.7185	0.7905	0.7566	0.8208	5.8778E-06	Gao Y (China)
0.6884	0.6566	0.7185	0.7932	0.7606	0.8225	2.0196E-06	Duan (China)
0.6884	0.6566	0.7185	0.7922	0.7589	0.8220	3.226E-06	M Pan (China)
0.6884	0.6566	0.7185	0.7891	0.7548	0.8198	9.0186E-06	Qin JJ (China)
0.6884	0.6566	0.7185	0.7893	0.7551	0.8198	8.295E-06	Poudel (Nepal)
0.6884	0.6566	0.7185	0.7853	0.7522	0.8150	1.1949E-05	Okuyan (Turkey)
0.6884	0.6566	0.7185	0.7906	0.7566	0.8209	5.8778E-06	Genc (Turkey)
0.6884	0.6566	0.7185	0.7904	0.7563	0.8209	6.6122E-06	Korkusuz (Turkey)
0.6884	0.6566	0.7185	0.7922	0.7589	0.8220	3.2827E-06	Bintoro (Surabaya, Indonesia)
0.6884	0.6566	0.7185	0.7909	0.7572	0.8211	5.0085E-06	Saji (Kanagawa, Japan)
0.6884	0.6566	0.7185	0.7821	0.7521	0.8095	7.3371E-06	Bilgir (Turkey)
0.6884	0.6566	0.7185	0.7887	0.7545	0.8192	9.3339E-06	Wang F (Wuhan, China)

Supplementary Table 2:

Pooled AUCs for D-dimer calculated with omitting a single study at a time. The first line (in bold) shows the summary from all studies with no omissions.

Pooled AUC Europe/NA	Lower Limit Europe/NA	Upper Limit Europe/NA	Pooled AUC Asia	Lower Limit Asia	Upper Limit Asia	p-value	Study omitted
0.7791	0.7431	0.8114	0.7856	0.6958	0.8544	0.86183	None
0.7846	0.7438	0.8205	0.7856	0.6958	0.8544	0.97986	Soon (Cambridge)
0.7615	0.7182	0.8000	0.7856	0.6958	0.8544	0.53160	Soares (Spain)
0.7784	0.7315	0.8192	0.7856	0.6958	0.8544	0.85104	Kaufmann (Austria)
0.7911	0.7573	0.8213	0.7856	0.6958	0.8544	0.87794	van Dam (Netherlands)
0.7778	0.7435	0.8086	0.7856	0.6958	0.8544	0.83132	Carlino (Italy)
0.7768	0.7267	0.8200	0.7856	0.6958	0.8544	0.82051	Gomez (Spain)
0.7791	0.7431	0.8114	0.7961	0.6938	0.8707	0.67502	Asghar (Pakistan)
0.7791	0.7431	0.8114	0.8077	0.7299	0.8672	0.38689	Tahtasakal (Turkey)
0.7791	0.7431	0.8114	0.7893	0.6826	0.8671	0.80740	Ke (China)
0.7791	0.7431	0.8114	0.7754	0.6712	0.8538	0.92743	Zhang J (China)
0.7791	0.7431	0.8114	0.7782	0.6748	0.8557	0.98167	Liu Q (China)
0.7791	0.7431	0.8114	0.7989	0.7099	0.8657	0.58671	Cheng S (China)
0.7791	0.7431	0.8114	0.7646	0.6668	0.8406	0.70703	Cheng A (China)
0.7791	0.7431	0.8114	0.7778	0.6734	0.8560	0.97432	Zeng HL (China)
0.7791	0.7431	0.8114	0.7807	0.6837	0.8543	0.96784	Bilgir (Turkey)

Supplementary Table 3

Pooled AUCs for urea calculated with omitting a single study at a time. The first line (in bold) shows the summary from all studies with no omissions.

Pooled AUC Europe/NA	Lower Limit Europe/NA	Upper Limit Europe/NA	Pooled AUC Asia	Lower Limit Asia	Upper Limit Asia	p-value	Study omitted
0.7891	0.7415	0.8299	0.8121	0.7659	0.8509	0.42437	None
0.7934	0.7430	0.8361	0.8121	0.7659	0.8509	0.52584	Soon (Cambridge)
0.7850	0.7337	0.8287	0.8121	0.7659	0.8509	0.36282	Soares (Spain)
0.7852	0.7344	0.8286	0.8121	0.7659	0.8509	0.36515	Kaufmann (Austria)
0.7881	0.7362	0.8320	0.8121	0.7659	0.8509	0.42128	de Michieli (Italy)
0.7869	0.7353	0.8308	0.8121	0.7659	0.8509	0.39882	Peiro (Spain)
0.7875	0.7366	0.8308	0.8121	0.7659	0.8509	0.40640	Cipriani (Italy)
0.7969	0.7500	0.8370	0.8121	0.7659	0.8509	0.59410	Smilowitz (USA)
0.7862	0.7361	0.8290	0.8121	0.7659	0.8509	0.37902	Goudot (France)
0.7950	0.7462	0.8365	0.8121	0.7659	0.8509	0.55548	Macias-Munoz (Spain)
0.7969	0.7523	0.8352	0.8121	0.7659	0.8509	0.58517	Myrhe (Norway)
0.7895	0.7376	0.8335	0.8121	0.7659	0.8509	0.45003	Harmouch (USA)
0.7899	0.7379	0.8339	0.8121	0.7659	0.8509	0.45753	Manocha (USA)
0.7929	0.7427	0.8354	0.8121	0.7659	0.8509	0.51268	Herold (Germany)
0.7775	0.7364	0.8138	0.8121	0.7659	0.8509	0.20345	Aloisio (Italy)
							Petersen-Uribe (Germany)
0.7928	0.7425	0.8355	0.8121	0.7659	0.8509	0.51208	(Germany)
0.7824	0.7318	0.8256	0.8121	0.7659	0.8509	0.31472	Salvatici (Italy)
0.7891	0.7415	0.8299	0.8184	0.7728	0.8566	0.30315	Asghar (Pakistan)
0.7891	0.7415	0.8299	0.8088	0.7588	0.8504	0.50928	Deng (China)
0.7891	0.7415	0.8299	0.8174	0.7696	0.8572	0.33105	Tahtasakal (Turkey)
0.7891	0.7415	0.8299	0.8115	0.7614	0.8532	0.45270	Liang (China)
0.7891	0.7415	0.8299	0.8088	0.7591	0.8502	0.50742	Chen L (China)
0.7891	0.7415	0.8299	0.8092	0.7605	0.8500	0.49423	Cao (China)
0.7891	0.7415	0.8299	0.8180	0.7707	0.8573	0.31939	Chen H (China)
0.7891	0.7415	0.8299	0.8136	0.7638	0.8548	0.41108	Wang Y (China)
0.7891	0.7415	0.8299	0.8119	0.7635	0.8523	0.43622	Ozyilmaz (Turkey)
0.7891	0.7415	0.8299	0.8164	0.7688	0.8560	0.34777	Zhang J (China)
0.7891	0.7415	0.8299	0.8072	0.7573	0.8489	0.54380	Luo Y (China)
0.7891	0.7415	0.8299	0.8208	0.7782	0.8566	0.25043	Ozdin (Turkey)
0.7891	0.7415	0.8299	0.8108	0.7605	0.8526	0.46780	Sun W (Wuhan, China)
0.7891	0.7415	0.8299	0.8029	0.7581	0.8412	0.62438	Shi S (Wuhan, China)
0.7891	0.7415	0.8299	0.8146	0.7651	0.8556	0.39030	Qin JJ (Wuhan, China)
0.7891	0.7415	0.8299	0.8014	0.7549	0.8410	0.66842	Zhu F (Shanghai, China)


Supplementary Table 4

Pooled AUCs for troponin calculated with omitting a single study at a time. The first line (in bold) shows the summary from all studies with no omissions.

Pooled AUC Europe/NA	Lower Limit Europe/NA	Upper Limit Europe/NA	Pooled AUC Asia	Lower Limit Asia	Upper Limit Asia	p-value	Study omitted
0.69910	0.64283	0.74995	0.86064	0.80530	0.90216	8.76545E-06	None
0.70017	0.63808	0.75570	0.86064	0.80530	0.90216	1.73829E-05	Soon (Cambridge)
0.69989	0.63872	0.75468	0.86064	0.80530	0.90216	1.5351E-05	Soares (Spain)
0.69206	0.63350	0.74503	0.86064	0.80530	0.90216	4.97628E-06	Maeda (USA)
0.69755	0.63714	0.75182	0.86064	0.80530	0.90216	1.1052E-05	Nagant (Belgium)
0.70750	0.65397	0.75584	0.86064	0.80530	0.90216	1.61647E-05	Pieri (Italy)
0.70545	0.64717	0.75771	0.86064	0.80530	0.90216	2.07354E-05	Kara (USA)
0.69668	0.63566	0.75147	0.86064	0.80530	0.90216	1.073E-05	Laguna-Goya (Spain)
0.70349	0.64457	0.75634	0.86064	0.80530	0.90216	1.79307E-05	Mueller (USA)
0.70895	0.65978	0.75367	0.86064	0.80530	0.90216	1.23311E-05	Donoso-Navarro (Spain)
0.70087	0.63878	0.75635	0.86064	0.80530	0.90216	1.86744E-05	Muinos (Spain)
0.69659	0.64033	0.74752	0.86064	0.80530	0.90216	6.40601E-06	Carlino (Italy)
0.68459	0.63518	0.73016	0.86064	0.80530	0.90216	7.25907E-07	Herold (Germany)
0.69130	0.63462	0.74276	0.86064	0.80530	0.90216	3.70937E-06	Quartuccio (Italy)
0.70026	0.63890	0.75519	0.86064	0.80530	0.90216	1.62707E-05	Myrhe (Norway)
0.69768	0.63823	0.75117	0.86064	0.80530	0.90216	1.01345E-05	Guirao (Spain)
0.70449	0.64556	0.75730	0.86064	0.80530	0.90216	1.99393E-05	Villa (Italy)
0.69800	0.63722	0.75255	0.86064	0.80530	0.90216	1.20541E-05	Ruscica (Italy)
0.69910	0.64283	0.74995	0.86179	0.79323	0.91019	7.37739E-05	Shi (China)
0.69910	0.64283	0.74995	0.86602	0.80686	0.90910	1.03533E-05	Ke (China)
0.69910	0.64283	0.74995	0.85088	0.79167	0.89548	4.6002E-05	Shang (China)
0.69910	0.64283	0.74995	0.87035	0.81733	0.90968	1.44626E-06	Zhang J (China)
0.69910	0.64283	0.74995	0.84044	0.79690	0.87609	5.4559E-06	Zhang (China)
0.69910	0.64283	0.74995	0.86650	0.80807	0.90914	8.39488E-06	Pan (China)
0.69910	0.64283	0.74995	0.86126	0.79939	0.90629	2.8198E-05	Han (China)
0.69910	0.64283	0.74995	0.86179	0.79323	0.91019	7.37739E-05	Shi (China)
0.69910	0.64283	0.74995	0.85909	0.80003	0.90283	1.99223E-05	Satis (Turkey)
0.69910	0.64283	0.74995	0.86546	0.80704	0.90821	9.28051E-06	Gao Y (China)
0.69910	0.64283	0.74995	0.86038	0.79911	0.90517	2.7228E-05	Saji (Japan)
0.69910	0.64283	0.74995	0.85836	0.79583	0.90404	4.15284E-05	Wang F (China)


Supplementary Table 5

Pooled AUCs for IL-6 calculated with omitting a single study at a time. The first line (in bold) shows the summary from all studies with no omissions.




Supplementary Figure 1

Flow diagram for identification and selection of studies regarding utility of D-dimer as a biomarker in vaccinated and/or variant cohorts.




Supplementary Figure 2

Flow diagram for identification and selection of studies regarding utility of CRP as a biomarker in vaccinated and/or variant cohorts.




Supplementary Figure 3

Flow diagram for identification and selection of studies regarding utility of troponin as a biomarker in vaccinated and/or variant cohorts.



Supplementary Figure 4

Flow diagram for identification and selection of studies regarding utility of urea as a biomarker in vaccinated and/or variant cohorts.



Supplementary Figure 5

Flow diagram for identification and selection of studies regarding utility of IL-6 as a biomarker in vaccinated and/or variant cohorts.

Acknowledgements

Many thanks to the following scientists and doctors who have interrogated their data further at our request.

Dr Jose Miguel Urria **Ardanaz**

Prof. Jeffrey **Berger**

Dr Francisco **Bernabeu Andreu**

Dr Alberto **Cipriani**

Dr Christina **Creel-Bulos**

Dr Tobias **Herold**

Dr Areeba **Kara** and Dr Warren **Gavin**

Dr Edy **Kim**

Dr Christoph **Kaufmann**

Dr Manuel **Morales**

Dr Peder Langeland **Myrhe**

Dr Carole **Nagant**

Dr Natalia **Pascual Gomez**

Mr Niels **Pouw** and Dr Jacobien **Hoogerwerf**

Dr Luca **Quartuccio**

Dr Morayma **Reyes Gil**

Dr Manuel **Rubio-Rivas**

Dr Maria **Salinas**

Dr Fatima **Sharif**

Dr Tao **Shen**

Dr Paul **van Dam**

Dr Erica **Villa**

Thank you!

We thank all patients and families affected by this pandemic who have contributed to the data needed for this work. We thank all healthcare, social care and essential workers that have soldiered on, regardless of personal risk.